StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $14.73 | $16.04 | +8.89% | 3.2M |
| 05-14 | $16.08 | $16.58 | +3.11% | 1.6M |
| 05-15 | $16.39 | $16.56 | +1.04% | 1.3M |
| 05-18 | $16.79 | $16.47 | -1.91% | 1.0M |
| 05-19 | $16.72 | $16.60 | -0.72% | 0.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Each factor shows OMDA's percentile within the scored universe — observational ranking, not a recommendation.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $78.05M | $260.21M | $184.36M | $116.33M |
Operating Income | $-4.78M | $-11.97M | $-15.25M | $-12.74M |
Net Income | $-2.97M | $-12.78M | $-17.94M | $-5.31M |
EPS (Diluted) | $-0.05 | $-0.35 | $-0.61 | $-0.98 |
Total Assets | $302.80M | $305.41M | $287.47M | $302.97M |
Total Liabilities | $68.68M | $75.73M | $70.12M | $88.76M |
Cash & Equivalents | $211.76M | $222.04M | $198.63M | $223.15M |
Free Cash Flow OCF − CapEx | $-11.91M | $16.93M | $-4.25M | $-13.85M |
Shares Outstanding | 59.24M | 58.43M | 57.89M | 57.32M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
OMDA is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.